VTL Vital Therapies Inc

Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast

Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast

SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its second quarter 2018 financial results after the market closes on Tuesday, August 7, 2018 followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review financial results and discuss other business matters.

The conference call dial-in numbers are (855) 765-5682 for domestic callers and (919) 825-3204 for international callers. The conference ID number for the call is 9287366.  Participants may access the live webcast via a link on the Vital Therapies website in the Investors Relations section under Events at: .  The webcast will be archived on the Company's website shortly after completion of the call.

For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 7:30 p.m. ET on August 7, 2018 to 7:30 p.m. ET on August 14, 2018. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 9287366. 

About Vital Therapies, Inc.

Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure.  The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials.  Vital Therapies, Inc. is based in San Diego, California.  Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.

Contact:



Vital Therapies, Inc. 

Al Kildani

Vice President, Investor Relations and Business Development

858-673-6840

EN
31/07/2018

Underlying

VTLVital Therapies Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vital Therapies Inc

 PRESS RELEASE
Free
VTL Vital Therapies...

Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarte...

Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarter Ended March 31, 2019 SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:  VTL) announced that it had filed its quarterly report on Form 10-Q today. The report was filed earlier than usual to facilitate the closing of the Company’s transaction with Immunic AG. As previously announced, the transaction has been approved by the stockholders of the Company and is expected to be consummated by mid-April. In connection with the closing of the transaction, Vital Therapies will change its name to Immun...

April 10, 2019 1 EN
 PRESS RELEASE
Free
VTL Vital Therapies...

Vital Therapies, Inc. Announces Stockholder Approval of Business Combi...

Vital Therapies, Inc. Announces Stockholder Approval of Business Combination with Immunic AG SAN DIEGO, April 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:  VTL) announced that its stockholders voted to approve the proposals required to complete the business combination with Immunic AG at a special meeting of Vital Therapies stockholders held earlier today.  Approximately 98.82% of the shares voted at the special stockholder meeting voted in favor of the Exchange Agreement proposal, with each of the other related proposals also receiving sufficient votes for approval. “We...

April 4, 2019 1 EN
 PRESS RELEASE
Free
VTL Vital Therapies...

Vital Therapies Reminds Stockholders to Vote For the Proposed Busines...

Vital Therapies Reminds Stockholders to Vote For the Proposed Business Combination With Immunic AG Of the Votes Received to Date, More than 98% are Voting in Favor of the Business CombinationMore Votes are Needed to Reach 50% of the Outstanding Shares Required for the Business Combination to Go ForwardEvery Vote is Important to Avoid Delay in Completion of the Business Combination SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL) would like to thank its stockholders for their support of the proposed business combination with Immunic AG and remind those stockholder...

March 27, 2019 1 EN
 PRESS RELEASE
Free
VTL Vital Therapies...

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommen...

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Vital Therapies Stockholders Vote “FOR” the Proposed Business Transaction With Immunic AG and All the Related Proposals SAN DIEGO, March 25, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL) announced today that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co., LLC (Glass Lewis) have both recommended that Vital Therapies stockholders vote “FOR” the proposed business combination with Immunic AG and the related proposals in the Company’s proxy statement/prospectus for the special meeting of its sto...

March 25, 2019 1 EN
 PRESS RELEASE
Free
VTL Vital Therapies...

Vital Therapies Announces 2018 Financial Results

Vital Therapies Announces 2018 Financial Results SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the year ended December 31, 2018. Recent Developments On January 6, 2019, we entered into an exchange agreement (the “Exchange Agreement”), with Immunic AG, or Immunic, and all of the current shareholders of Immunic.  Under this agreement, all Immunic shareholders will exchange all of their Immuni...

March 4, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch